Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-5db6c4db9b-v64r6 Total loading time: 0 Render date: 2023-03-25T12:04:42.852Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

Chapter 19 - Principles of Antiseizure Drug Management

Published online by Cambridge University Press:  11 October 2019

By
Georgia Montouris
Edited by
Vibhangini S. Wasade  and
Marianna V. Spanaki
Vibhangini S. Wasade
Affiliation:
Henry Ford Medical Group HFHS, Michigan
Marianna V. Spanaki
Affiliation:
Wayne State University, Michigan
Get access

Summary

Seizures are categorized as unprovoked or provoked, and the former may lead to the diagnosis of epilepsy. The term unprovoked seizure refers to a seizure of unknown etiology or that occurs in relation to a presenting brain lesion or progressive nervous system disorder. Provoked seizures are due to an acute condition such as toxic or metabolic disturbance, head trauma, or acute stroke. About 30% of patients with unprovoked seizures, which are nearly always generalized tonic–clonic convulsions, are seen by physicians after only a single attack. Studies have now established high-risk groups for recurrence after a single unprovoked seizure. The risk for epilepsy is greatly increased in the presence of an abnormal electroencephalogram (EEG), history of brain injury, and family history of epilepsy.1 Age of onset may impact the choice of antiseizure drug (ASD). Etiologies often vary with age of onset. Prognosis, consequences of etiology, and response to treatment may vary depending on age and comorbid conditions.

Type
Chapter
Information
Understanding Epilepsy
A Study Guide for the Boards
 , pp. 357 - 367
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Purchase

Buy Book

Buy print or eBook[Opens in a new window]

References

Freeman, JM, Pedley, TA. Indications for treatment. In: Engel, J Jr., Pedley, TA, eds., Epilepsy: A Comprehensive Textbook. 2nd edn. Philadelphia: Lippincott Williams & Wilkins; 2008:1119–1123.Google Scholar
Rust, RS, Volpe, JJ. Neonatal seizures. In: Dodson, WE, Pellock, JM, eds., Pediatric Epilepsy: Diagnosis and Therapy. New York: Demos Publications; 1993:107–128.Google Scholar
Volpe, JJ. Neonatal seizures. In: Volpe, JJ, ed., Neurology of the Newborn. Philadelphia: Saunders; 1987:129–158.Google Scholar
Aicardi, J. Neonatal and infantile seizures. In: Morselli, PL, Pippenger, CE, Penry, JK, eds., Antiepileptic Drug Therapy in Pediatrics. New York: Raven Press; 1983:103–113.Google Scholar
Lockman, LA, Kriel, R, Zaske, D, Thompson, T, Virnig, N. Phenobarbital dosage for control of neonatal seizures. Neurology. 1979;29(11):1445–1449.CrossRefGoogle ScholarPubMed
Rust, RS, Dodson, WE. Phenobarbital: absorption, distribution and excretion. In: Levy, RH, Dreifuss, FE, Mattson, RH, Meldrum, BS, Penry, JK, eds., Antiepileptic Drugs. 3rd edn. New York: Raven Press; 1989.Google Scholar
Fischer, JH, Lockman, LA, Zaske, D, Kriel, R. Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology. 1981;31(8):1042–1044.CrossRefGoogle ScholarPubMed
Painter, MJ, Pippenger, C, Wasterlain, C, et al. Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. Neurology. 1981;31(9):1107–1112.CrossRefGoogle ScholarPubMed
Gilman, JT, Gal, P, Duchowny, MS, Weaver, RL, Ransom, JL. Rapid sequential phenobarbital treatment of neonatal seizures. Pediatrics. 1989;83(5):674–678.Google ScholarPubMed
Gal, P, Toback, J, Boer, HR, Erkan, NV, Wells, TJ. Efficacy of phenobarbital monotherapy in treatment of neonatal seizures – relationship to blood levels. Neurology. 1982;32(12):1401–1404.CrossRefGoogle ScholarPubMed
Thong, YH, Abramson, DC. Continuous infusion of diazepam in infants with severe recurrent convulsions. Med Ann Dist Columbia. 1974;43(2):63–65.Google ScholarPubMed
Dodson, WE. Antiepileptic drug use in newborns and infants. In: Pedley, TA, Meldrum, BS, eds., Recent Advances in Epilepsy. Edinburgh: Churchill Livingstone; 1983:231–249.Google Scholar
Morselli, PL. Development of physiological variables important for drug kinetics. In: Morselli, PL, Pippenger, CE, Penry, JK, eds., Antiepileptic Drug Therapy in Pediatrics. New York: Raven Press; 1983:1–12.Google Scholar
Bourgeois, BF, Dodson, WE. Phenytoin elimination in newborns. Neurology. 1983;33(2):173–178.CrossRefGoogle ScholarPubMed
Morselli, PL, Baruzzi, A. Serum Levels and Pharmokinetics of Anticonvulsants in the Management of Seizure Disorders. Chicago: Year Book Medical Publishers; 1978.Google Scholar
Dodson, WE. Phenytoin elimination in childhood: effect of concentration-dependent kinetics. Neurology. 1980;30(2):196–199.CrossRefGoogle ScholarPubMed
Dodson, WE. Nonlinear kinetics of phenytoin in children. Neurology. 1982;32(1):42–48.CrossRefGoogle ScholarPubMed
Watanabe, K, Kuroyanagi, M, Hara, K, Miyazaki, S. Neonatal seizures and subsequent epilepsy. Brain Dev. 1982;4(5):341–346.CrossRefGoogle ScholarPubMed
Holden, KR, Mellits, ED, Freeman, JM. Neonatal seizures. I. Correlation of prenatal and perinatal events with outcomes. Pediatrics. 1982;70(2):165–176.Google ScholarPubMed
Bergman, I, Painter, MJ, Crumrine, PK. Neonatal seizures. Semin Perinatol. 1982;6(1):54–67.Google ScholarPubMed
Mizrahi, EM, Kellaway, P. Characterization and classification of neonatal seizures. Neurology. 1987;37(12):1837–1844.CrossRefGoogle ScholarPubMed
Cloyd, J. Commonly Used Antiepileptic Drugs: Age-Related Pharmacokinetics. Woburn, MA: Butterworth-Heinemann; 1997.Google Scholar
Willmore, J. Commonly used antiepileptic drugs: age related efficacy. In: Rowan, AJ, Ramsay, E, eds., Seizures and Epilepsy in the Elderly. Woburn, MA: Butterworth-Heinemann; 1997:229–238.Google Scholar
Krumholz, A, Wiebe, S, Gronseth, GS, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84(16):1705–1713.CrossRefGoogle ScholarPubMed
Fields, MC, Labovitz, DL, French, JA. Hospital-onset seizures: an inpatient study. JAMA Neurol. 2013;70(3):360–364.CrossRefGoogle Scholar
Gidal, BE, French, JA, Grossman, P, Le Teuff, G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology. 2009;72(5):419–425.CrossRefGoogle ScholarPubMed
Hessen, E, Lossius, MI, Gjerstad, L. Antiepileptic monotherapy significantly impairs normative scores on common tests of executive functions. Acta Neurol Scand. 2009;119(3):194–198.CrossRefGoogle ScholarPubMed
Motamedi, G, Meador, K. Epilepsy and cognition. Epilepsy Behav. 2003;4 Suppl 2:S25–38.CrossRefGoogle ScholarPubMed
Meador, KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 2006;68(1):63–67.CrossRefGoogle ScholarPubMed
Yang, CY, Dao, RL, Lee, TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011;77(23):2025–2033.CrossRefGoogle ScholarPubMed
Mockenhaupt, M, Messenheimer, J, Tennis, P, Schlingmann, J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134–1138.CrossRefGoogle ScholarPubMed
Gelisse, P, Genton, P, Kuate, C, et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia. 2004;45(10):1282–1286.CrossRefGoogle ScholarPubMed
Perucca, E, Gram, L, Avanzini, G, Dulac, O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39(1):5–17.CrossRefGoogle ScholarPubMed
Vecht, CJ, van Breemen, M. Optimizing therapy of seizures in patients with brain tumors. Neurology. 2006;67(12 Suppl 4):S10–13.CrossRefGoogle ScholarPubMed
Michelucci, R. Optimizing therapy of seizures in neurosurgery. Neurology. 2006;67(12 Suppl 4):S14–18.CrossRefGoogle ScholarPubMed
Bazil, CW. Antiepileptic drugs in the 21st century. CNS Spectr. 2001;6(9):756–762, 765.CrossRefGoogle ScholarPubMed
Lacerda, G, Krummel, T, Sabourdy, C, Ryvlin, P, Hirsch, E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology. 2006;67(12 Suppl 4):S28–33.CrossRefGoogle ScholarPubMed
Israni, RK, Kasbekar, N, Haynes, K, Berns, JS. Use of antiepileptic drugs in patients with kidney disease. Semin Dial. 2006;19(5):408–416.CrossRefGoogle ScholarPubMed
Sheth, RD. Metabolic concerns associated with antiepileptic medications. Neurology. 2004;63(10 Suppl 4):S24–29.CrossRefGoogle ScholarPubMed
Ahmed, SN, Siddiqi, ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156–164.CrossRefGoogle ScholarPubMed
Mula, M, Hesdorffer, DC, Trimble, M, Sander, JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia. 2009;50(5):1072–1076.CrossRefGoogle ScholarPubMed
Pack, AM, Morrell, MJ, Marcus, R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol. 2005;57(2):252–257.CrossRefGoogle ScholarPubMed
Pack, A. Effects of treatment on endocrine function in patients with epilepsy. Curr Treat Options Neurol. 2005;7(4):273–280.CrossRefGoogle ScholarPubMed
Pack, AM, Morrell, MJ, Randall, A, McMahon, DJ, Shane, E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586–1593.CrossRefGoogle ScholarPubMed
Dulac, O, Leppick, IE, Chadwick, DW, Specchio, L. Starting and stopping treatment. In: Engel, J, Pedley, TA, Aicardi, J, eds., Epilepsy: A Comprehensive Textbook. 2nd edn. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008:1301–1310.Google Scholar
Camfield, P, Camfield, C. The frequency of intractable seizures after stopping AEDs in seizure-free children with epilepsy. Neurology. 2005;64(6):973–975.CrossRefGoogle ScholarPubMed
Nakazawa, Y, Ishida, S, Maeda, H, Sakurai, S, Motooka, H. Prognosis of epilepsy withdrawn from antiepileptic drugs. Psychiatry Clin Neurosci. 1995;49(3):163–168.CrossRefGoogle ScholarPubMed
Specchio, LM, Tramacere, L, La Neve, A, Beghi, E. Discontinuing antiepileptic drugs in patients who are seizure-free on monotherapy. J Neurol Neurosurg Psychiatry. 2002;72(1):22–25.CrossRefGoogle ScholarPubMed
So, NK. Recurrence, remission, and relapse of seizures. Cleve Clin J Med. 1993;60(6):439–444.CrossRefGoogle ScholarPubMed
Armijo, JA, Adin, J. [Pharmacological basis for withdrawal of antiepileptic drugs]. Rev Neurol. 2000;30(4):336–350.Google ScholarPubMed
Sirven, JI, Sperling, M, Wingerchuk, DM. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2001(3):Cd001902.Google Scholar
Berg, AT, Shinnar, S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology. 1994;44(4):601–608.CrossRefGoogle ScholarPubMed
Tennison, M, Greenwood, R, Lewis, D, Thorn, M. Discontinuing antiepileptic drugs in children with epilepsy: a comparison of a six-week and a nine-month taper period. N Engl J Med. 1994;330(20):1407–1410.CrossRefGoogle Scholar
Peters, AC, Brouwer, OF, Geerts, AT, et al. Randomized prospective study of early discontinuation of antiepileptic drugs in children with epilepsy. Neurology. 1998;50(3):724–730.CrossRefGoogle ScholarPubMed
Duncan, JS, Shorvon, SD, Trimble, MR. Withdrawal symptoms from phenytoin, carbamazepine and sodium valproate. J Neurol Neurosurg Psychiatry. 1988;51(7):924–928.CrossRefGoogle ScholarPubMed
Schmidt, D, Loscher, W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol Scand. 2005;111(5):291–300.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×